ProCE Banner Activity

PARP Inhibitors in Settings Beyond Metastatic Castration-Resistant Prostate Cancer

Clinical Thought
In this commentary, 2 experts discuss the potential for PARP inhibitor combinations as neoadjuvant therapy and in the setting of metastatic castration-sensitive disease.

Released: April 02, 2021

Expiration: April 01, 2022

No longer available for credit.

Share

Faculty

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Neal D. Shore

Neal D. Shore, MD, FACS

Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer TEXT Only

Faculty Disclosure

Primary Author

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has received funds for research support from Bayer, Clovis, and Sanofi Genzyme and consulting fess from Advance Accelerator Applications, Bayer, Dendreon, Pfizer, and Roivant.

Neal D. Shore, MD, FACS

Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, has disclosed that he has received consulting fees from AbbVie, Ambry, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Clovis, Dendreon, Exact Imaging, FerGene, Ferring, Foundation Medicine, Invitae, Janssen, MDx Health, Merck, Myovant, Myriad, Nymox, Pfizer, Plat Q, Sanofi Genzyme, and Tolmar and fees for non-CME/CE services from Astellas, Bayer, Clovis, Janssen, and Pfizer.